Article

Identifying Biomarkers of Subclinical Diabetes

Islet Cell Biology and Regenerative Medicine, Joslin Diabetes Center, Boston, Massachusetts, USA.
Diabetes (Impact Factor: 8.47). 08/2012; 61(8):1925-6. DOI: 10.2337/db12-0599
Source: PubMed
1 Follower
 · 
92 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pancreatic β-cell failure which invariably accompanies insulin resistance in the liver and skeletal muscle is a hallmark of type-2 diabetes mellitus (T2DM). The persistent hyperglycemia of T2DM is often treated with anti-diabetic drugs with or without subcutaneous insulin injections, neither of which mimic the physiological glycemic control seen in individuals with fully functional pancreas. A sought after goal for the treatment of T2DM has been to harness the regenerative potential of pancreatic β-cells that might obviate a need for exogenous insulin injections. A new study towards attaining this aim was reported by Yi et al, who have characterized a liver-derived protein, named betatrophin, capable of inducing pancreatic β-cell proliferation in mice. Using a variety of in vitro and in vivo methods, Yi et al, have shown that betatrophin was expressed mainly in the liver and adipose tissue of mice. Exogenous expression of betatrophin in the liver led to dramatic increase in the pancreatic β-cell mass and higher output of insulin in mice that also concomitantly elicited improved glucose tolerance. The authors discovered that betatrophin was also present in the human plasma. Surprisingly, betatrophin has been previously described by three other names, i.e., re-feeding-induced fat and liver protein, lipasin and atypical angiopoeitin-like 8, by three independent laboratories, as nutritionally regulated liver-enriched factors that control serum triglyceride levels and lipid metabolism. Yi et al demonstration of betatrophin, as a circulating hormone that regulates β-cell proliferation, if successfully translated in the clinic, holds the potential to change the course of current therapies for diabetes.
    12/2013; 4(6):234-7. DOI:10.4239/wjd.v4.i6.234
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to identify blood metabolites associated with variation primarily in residual feed intake (RFI) in two populations of beef steers at the University of Guelph and University of Alberta, Canada, representing the discovery and validation populations, respectively. Other productivity performance traits including average body weight (ABW), average feed intake (AFI), dry matter intake (DMI) and average daily gain (ADG) were also investigated. In the discovery population, blood plasma samples were obtained from 32 steers (16 high- and 16 low- RFI, from a population of 112 steers and maximizing the divergence between groups for RFI) at three periods; 1, 2 and 3, corresponding to week 2, 6 and 10 respectively of the 140 d feeding and performance test. In the validation population, blood samples were obtained from 20 (10 high and 10 low RFI) steers from periods 1 and 2 corresponding to week 2 and 6 of a 90 d feeding test period. Metabolite concentrations in plasma were determined using nuclear magnetic resonance (NMR) and multiple regression analysis was performed in SAS 9.1. Creatine and glycine were associated (P<0.05) with RFI in period 1 accounting for 36.3% of the phenotypic variation in RFI. At period 2, threonine, carnitine, acetate, creatine, phenylalanine, lysine, citrate, betaine, glutamate and hippurate were significant (P<0.05) and accounted for 74.2% of the variation in RFI. At period 3, hydroxyisobutyrate, tyrosine and formate were significant (P<0.05) and accounted for 52.1% of the variation in RFI. In the validation population, three metabolites (creatine, carnitine and hippurate) were significant (P<0.05) in both discovery and validation populations and these three metabolites accounted for 32% of the phenotypic variation in RFI in the validation population. Some of the metabolites associated with RFI were also associated with other performance traits discussed in subsequent sections. Metabolic networks for RFI in each period were reconstructed using IPA and suggested that the biological processes associated with RFI were involved in energy and protein metabolism as well as metabolism of urea and methane. The analysis of metabolites and evaluation of biological processes create a better understanding of the metabolic processes that affect RFI. Upon further validation, these indicators may have potential to be utilized as biomarkers to enhance the selection of beef cattle.
    Livestock Science 07/2014; 165. DOI:10.1016/j.livsci.2014.03.002 · 1.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with carboxyl-ester lipase-maturity-onset diabetes of the young (CEL-MODY) display distinct disease stages toward the development of monogenic diabetes and exocrine pancreatic disease. The finding of differentially increased proteins, some related to MAPK signaling, in a discovery proteomics study of secretin-stimulated duodenal juice in three CEL-MODY patients, prompted us to monitor their abundance in an extensive number of CEL-MODY subjects at different disease stages and controls using targeted proteomics. In the current study, we demonstrate the feasibility of selected reaction monitoring assays to quantify protein levels in secretin-stimulated duodenal juice. Furthermore, we define a set of five peptides for potential use as diagnostic tests in CEL-MODY patients. Finally, we propose a further set of seven proteins with a likely pathogenic role in CEL-MODY disease progression.
    Journal of Proteome Research 11/2014; 14(1). DOI:10.1021/pr500750z · 5.00 Impact Factor

Preview

Download
1 Download
Available from